Share Issue/Capital Change • Mar 14, 2022
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Oslo, Norway, 14 March 2022: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 14 March 2022 exercised a total of 2,750 options distributed as follows:
Each option gives a right to receive one share in the Company. The share options are described in note 7 and 23 in Photocure's annual financial statements for 2020.
Following the exercise, the Board of Directors, pursuant to authorisation granted by the Company's Annual General Meeting, has decided to increase the Company's share capital by NOK 1,375 by issuing 2,750 new shares, of par value NOK 0.50. Subsequent to the transaction, Photocure's share capital will be NOK 13,488,285 divided into 26,976,570 shares, each share having a par value of NOK 0.50 and carrying one vote in the Company's general meeting.
No primary insiders have exercised share options.
Photocure CFO Erik Dahl Tel: +47 450 55 000 Email: [email protected]
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.